Updated AACE guidance recommends Kerendia for diabetes-related kidney disease
Click Here to Manage Email Alerts
The American Association of Clinical Endocrinology has issued a grade-A recommendation to use Kerendia for certain patients with chronic kidney disease associated with type 2 diabetes.
The recommendation is part of a larger update to the AACE’s guidance on diabetes care, which includes 170 new and updated recommendations on prevention, diagnosis and treatment.
“The latest AACE guideline helps patients and their care teams better understand the treatments and resources available and equips them with the latest scientific evidence to aid critical decisions for optimal disease management,” Amit Sharma, MD, vice president of medical affairs in the cardiovascular and renal division at Bayer, said in a press release from the company. “AACE’s latest guideline update reinforces Kerendia as a fundamental pillar in the treatment algorithm for preserving kidney function and providing dual cardiorenal risk reduction in chronic kidney disease associated with type 2 diabetes patients with a broad range of chronic kidney disease severity.”
Kerendia (finerenone, Bayer) is a first-in-class non-steroidal mineralocorticoid receptor antagonist, according to the release. The drug was first approved by the FDA in July 2021 for patients with chronic kidney disease associated with type 2 diabetes to reduce the risk for end-stage kidney disease, cardiovascular death, sustained estimated glomerular filtration rate (eGFR) decline, hospitalization for heart failure and non-fatal myocardial infarction. According to the release, patients with chronic kidney disease associated with type 2 diabetes are three times more likely than those with type 2 diabetes alone to die from a cardiovascular-related cause.
Earlier this month, the American Diabetes Association and Kidney Disease: Improving Global Outcomes recommended including finerenone in treatment regimens for patients who have an eGFR of 25 mL/min/1.73 m2 or greater and normal serum potassium concentration and albuminuria (urine albumin-to-creatinine ratio 30 mg/g) despite receiving the maximum tolerated dose of a renin-angiotensin-system inhibitor.